Table 4.
Modification of clinical score and respiratory function tests after gentamicin treatment.
| Group A n = 9 |
Group B n = 4 |
Group C n = 5 |
|||||||
| D0 | D15 | p | D0 | D15 | p | D0 | D15 | p | |
| CFCS | 30(8) | 21(8) | 0.007 | 25(1) | 22 (1) | NS | 23.5(2) | 23(3) | NS |
| FEV1(L) | 1.82(0.8) | 2.07(0.8) | 0.04 | 1.68(0.4) | 1.77(0.3) | NS | 2(0.3) | 2.12(0.4) | NS |
| FVC(L) | 2.2(1) | 2.36(0.9) | NS | 2.08(0.6) | 2.14(0.5) | NS | 2.93(0.5) | 3(0.4) | NS |
| FEF25–75(L) | 1.54(1.1) | 1.95(1.06) | NS | 1.91(0.9) | 1.96(0.8) | NS | 1.93(1.8) | 1.99(1.8) | NS |
Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. CFCS refers to the Cystic Fibrosis Clinical Score. FEV1, FVC, FEF25–75 as defined in Table 2 and are expressed as absolute values. Data are described as mean (SD). Comparison with Wilcoxon test.